This article is more than 5 years old. Information may no longer be current.
Top stories in hematology/oncology: FDA approves Nubeqa for prostate cancer subset, certain medications may increase breast cancer risk
Among the top stories in hematology/oncology last week were the FDA approving Nubeqa for the treatment of nonmetastatic castration-resistant prostate cancer and a study that found certain medications were linked to increased risk for breast cancer.
Other highlights included the FDA approving Keytruda for recurrent squamous cell carcinoma of the esophagus, research that suggested pregnancy was associated with increased risk for transfusion reactions among women who received blood products and a study that indicated elderly patients with HIV and cancer had worse clinical outcomes than patients without HIV.
FDA approves Nubeqa for prostate cancer subset
The FDA approved darolutamide for treatment of men with nonmetastatic castration-resistant prostate cancer. Read more.
Certain medications linked to increased breast cancer risk
Women with high cumulative exposure to dibutyl phthalate through medications appeared to be at increased risk for ER-positive breast cancer, according to results of a retrospective study published in Journal of Clinical Oncology. Read more.
FDA approves Keytruda for recurrent squamous cell carcinoma of the esophagus
The FDA approved pembrolizumab as monotherapy for certain patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus. Read more.
Pregnancy, preeclampsia linked to higher risk for transfusion reactions
Pregnancy appeared associated with increased risk for transfusion reactions among women who received blood products, with preeclampsia as the most significant risk factor for complications, according to study results published in Blood Advances. Read more.
HIV infection worsens cancer outcomes among elderly
Elderly patients with HIV and cancer appeared to have worse clinical outcomes than patients without HIV, according to results of a retrospective study published in JAMA Oncology. Read more.